These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9066713)

  • 1. The natural history of monoclonal gammopathy of undetermined significance. A 5- to 20-year follow-up of 263 cases.
    Pasqualetti P; Festuccia V; Collacciani A; Casale R
    Acta Haematol; 1997; 97(3):174-9. PubMed ID: 9066713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance.
    Pasqualetti P; Casale R
    Biomed Pharmacother; 1997; 51(2):74-8. PubMed ID: 9161471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal gammopathy of undetermined significance and solitary plasmacytoma. Implications for progression to overt multiple myeloma.
    Kyle RA
    Hematol Oncol Clin North Am; 1997 Feb; 11(1):71-87. PubMed ID: 9081205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A long-term study of prognosis in monoclonal gammopathy of undetermined significance.
    Kyle RA; Therneau TM; Rajkumar SV; Offord JR; Larson DR; Plevak MF; Melton LJ
    N Engl J Med; 2002 Feb; 346(8):564-9. PubMed ID: 11856795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
    J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant transformation in IgM monoclonal gammopathy of undetermined significance.
    Montoto S; Rozman M; Rosiñol L; Nadal E; Giné E; Aymerich M; Ferrer A; Esteve J; Bosch F; López-Guillermo A; Bladé J; Montserrat E
    Semin Oncol; 2003 Apr; 30(2):178-81. PubMed ID: 12720132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance.
    Kyle RA; Therneau TM; Rajkumar SV; Remstein ED; Offord JR; Larson DR; Plevak MF; Melton LJ
    Blood; 2003 Nov; 102(10):3759-64. PubMed ID: 12881316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal gammopathy of undetermined significance (MGUS).
    Kyle RA
    Baillieres Clin Haematol; 1995 Dec; 8(4):761-81. PubMed ID: 8845571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance.
    Blade J; Lopez-Guillermo A; Rozman C; Cervantes F; Salgado C; Aguilar JL; Vives-Corrons JL; Montserrat E
    Br J Haematol; 1992 Jul; 81(3):391-4. PubMed ID: 1390212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal gammopathy of undetermined significance.
    Kyle RA
    Blood Rev; 1994 Sep; 8(3):135-41. PubMed ID: 7819815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma cell neoplasms and related entities-evolution in diagnosis and classification.
    Fend F; Dogan A; Cook JR
    Virchows Arch; 2023 Jan; 482(1):163-177. PubMed ID: 36414803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A long-term observation of development from monoclonal gammopathy of undetermined significance (MGUS) into primary amyloidosis].
    Kanoh T; Yago K; Okuma M
    Rinsho Ketsueki; 1990 Oct; 31(10):1740-4. PubMed ID: 2255066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation.
    Naina HV; Harris S; Dispenzieri A; Cosio FG; Habermann TM; Stegall MD; Dean PG; Prieto M; Kyle RA; Rajkumar SV; Leung N
    Am J Nephrol; 2012; 35(4):365-71. PubMed ID: 22473253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal gammopathy of undetermined significance (MGUS)-31 year follow up of a community study.
    Colls BM
    Aust N Z J Med; 1999 Aug; 29(4):500-4. PubMed ID: 10868527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malignant transformation of monoclonal gammopathy of undetermined significance: cumulative incidence and prognostic factors.
    Van De Donk N; De Weerdt O; Eurelings M; Bloem A; Lokhorst H
    Leuk Lymphoma; 2001 Aug; 42(4):609-18. PubMed ID: 11697489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal gammopathy of undetermined significance.
    Kyle RA; Rajkumar SV
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):102-14. PubMed ID: 16231848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rapid development of primary amyloidosis after two years' follow-up of monoclonal gammopathy of undetermined significance (MGUS)].
    Kanoh T; Inoue M; Okuma M
    Rinsho Ketsueki; 1993 Aug; 34(8):952-6. PubMed ID: 8411650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece.
    Anagnostopoulos A; Evangelopoulou A; Sotou D; Gika D; Mitsibounas D; Dimopoulos MA
    Ann Hematol; 2002 Jul; 81(7):357-61. PubMed ID: 12185503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance.
    Kyle RA; Therneau TM; Rajkumar SV; Offord JR; Larson DR; Plevak MF; Melton LJ
    Semin Oncol; 2003 Apr; 30(2):169-71. PubMed ID: 12720130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.